Efficacy and safety of Andrographis paniculata for the treatment of mild COVID -19 infection
Keywords:
effectiveness, safety, Andrographis paniculata, andrographolide, COVID-19Abstract
Objective : A study was conducted to investigate the effectiveness and safety of Andrographis
paniculata in treating patients with COVID-19. Patients received a daily dose of 84 mg of
andrographolide in capsule form.
Methods : This quasi-experimental study, conducted from June 2021 to December 2022,
involved 145 COVID-19 patients. They were given A. paniculata capsules, each containing 350
mg of andrographolide, at a dosage of 7 mg per capsule. The prescribed regimen was 4
capsules taken three times a day before meals over a period of 5 days. Clinical symptoms
were monitored using a visual analog scale, adverse drug reactions were recorded, and medication adherence was assessed through follow-up frequency. Effectiveness was
evaluated on days 1, 3, 6, and 14 by measuring the total score of 12 symptoms.
Results : The study demonstrated a statistically significant decrease in the total score of COVID-19 symptoms from day 3 onwards. Patients with asymptomatic and mild symptoms showed improvements of 14.48% and 84.83%, respectively. Significant reductions were observed in the number of patients experiencing fever, sore throat, difficulty breathing, headache, and muscle pain by the 3rd day of treatment. After 14 days, 67.59% of patients had recovered, with an average treatment duration of 10.32 ± 6.77 days. Notably, 98.62% of patients reported no side effects from A. paniculata.
Conclusion : A. paniculata in capsule form, with a daily dosage of 84 mg of andrographolide,
has proven to be effective and safe for treating COVID-19. The recommended duration of
treatment is 5 days. It is crucial to note that the typical daily dosage range for andrographolide in treating COVID-19 is between 60 and 180 mg.
Keywords : effectiveness, safety, Andrographis paniculata, andrographolide, COVID-19
References
World Health Organization. Listings of WHO’s response to COVID-19. [Internet]. [cited 2022 February 22]. Available from: https://www.who.int/news/item/29-06-2020- covidtimeline.
Department of Thai traditional and alternative medicine. Instruction for the use of Andrographis paniculate for the Coronavirus disease 2019: COVID – 19 epidemic situation. Nonthaburi. 2021(in Thai).
National Drug Information. Announcement of the National drug information committees about national list of essential herbal medicine (2nd issue) 2021. Thai government gazette [Internet]. [cited 2021 October 18]. Available from http://www.ratchakitcha.soc.go.th/DATA/PDF/2564/E/120/T_0046.PDF.
Benjapholpitak A, Wisittanon K, Sawangtham T, Thanirat T, Wanarat K. Conclusion of report on the use of Andrographis paniculate to treat COVID – 19 patients. J Thai Trad Alt Med. 202;19(1):229-33 (in Thai).
Kumar RA, Sridevi K, Kumar NV, Nanduri S, Rajagopal S. Anticancer and immunostimulatory compounds from Andrographis paniculata. J Ethnopharmacol. 2004;92(2-3):291-5.
Churiyah, Pongtuluran OB, Rofaani E, Tarwadi. Antiviral and immunostimulant activities of Andrographis paniculata.Hayati Journal of Biosciences. 2015;22(2):67-72.
Puri A, Saxena R, Saxena RP, Saxena KC, Srivastava V, Tandon Js. Immunostimulant agents from Andrographis paniculata. J Nat Prod. 1993;56(7):995-9.
Caceres DD, Hancke JL, Burgos RA, Wikman GK. Prevention of common colds with Andrographis paniculata dried extract. A Pilot double blind trial. Phytomedicine. 1997;4(2):101-4.
Chinese Patent CN1165302C. Medical use of andrographolide and its derivatives. [Internet]. 2003 [cited 2021 October 18]. Available from: https//patents.google.com/patent/CN1165302c/en.
Chinese Patent CN1454592A. Medical use of andrographolide and its derivatives. [Internet]. 2003[cited 2021 October 18]. Available from: https//patents.google.com/patent/CN1454592A/en.
Yan YM, Shen X, Cao YK, Zhang JJ, Wang Y, Cheng YX. Discovery of anti-2019-nCoV agents from 38 Chinese patent drugs toward respiratory diseases via docking screening. Preprints. 2020;2020020254 (doi: 10.20944/preprints202002.0254.v2).
Department of Thai traditional and alternative medicine. Andrographis paniculata for the COVID – 19 patients [Internet]. [cited 2021 July 6]. Available fromhttps://www.tm.mahidol.ac.th/research/News&Events/2021_03_05/1751396_FTJvsCOVID5MAR2021.pdf?fbclid=IwAR2hi1oNj9WatR_mV3zHg5y0yOBGvQOX3HO8lXM5ejA3Mr2UgL7zRwJbzIY (in Thai).
Satayavivad J. Andrographis Paniculate : From Integrated Research to Clinical Use as Anti COVID-19. J Chulabhorn Royal Acad [Internet]. 2022 Jan. 31 [cited 2023 Dec. 19];4(1):1-14. Available from: thaijo.org/index.php/jcra/article/view/255804 (in Thai).
Lwanga SK, Lemeshow S, Organization WH. Sample size determination in health studies: a practical manual: World Health Organization; 1991.
Greenberg SB. Update on Human Rhinovirus and Coronavirus Infections. Seminars in respiratory and critical care medicine. 2016;37(4):555-71.
Songvut P, Suriyo T, Panomvana D, Rangkadilok N, Satayavivad J. A comprehensive review on disposition kinetics and dosage of oral administration of Andrographis paniculata, an alternative herbal medicine, in co-treatment of coronavirus disease. Frontiers in pharmacology. 2022;13:952660.
Mishra S, Sangwan N, Sangwan R. Andrographis paniculata (Kalmegh): A review. Pharmacog Rev. 2007;1:283-98.
Rattanaraksa D, et al. The Efficacy and Safety of Andrographis paniculate Extract for Treatment of COVID-19 Patients with Mild Symptoms, Nakhonpathom Hospital. Region 4-5 Medical Journal. 2021;40(2):269-82 (in Thai).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Mahasarakham Hospital Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
วารสารนี้เป็นลิขสิทธิ์ของโรงพยาบาลมหาสารคาม
